SAN DIEGO, Feb. 19, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 56 of its Science Bytes podcast, featuring Dr. Lindy Carlstrom, Global Medical Affairs Manager for Acute Care. In this episode, Carlstrom and host Josh Casey discuss how high-sensitivity troponin (hs troponin) is transforming early cardiac diagnosis and improving emergency department efficiency.

SAN DIEGO, Feb. 18, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced that members of its management team will present at the Raymond James 47th Annual Institutional Investor Conference. The Company's presentation is scheduled for Tuesday, March 3, 2026, at 1:40 p.m.

Public Sector Pension Investment Board lifted its stake in shares of QuidelOrtho Corporation (NASDAQ: QDEL) by 17.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 264,853 shares of the company's stock after buying an additional 38,935 shares during the quarter. Public

QuidelOrtho inks Lifotronic supply deal, adding 70+ assays and new analyzer platforms to boost global immunoassay reach and recurring revenue potential.

/PRNewswire/ -- QuidelOrtho ha firmado un acuerdo de suministro estratégico a largo plazo con Lifotronic Technology Co., Ltd. (Lifotronic Technology Co., Ltd.,

/PRNewswire/ -- QuidelOrtho ist mit Lifotronic Technology Co., Ltd. eine langfristige strategische Liefervereinbarung eingegangen (Lifotronic Technology Co.,

QuidelOrtho (NASDAQ: QDEL - Get Free Report) and Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings. Profitability This table compares QuidelOrtho and Oramed Pharmaceuticals'

QDEL beats Q4 estimates as Labs and global growth lift sales, but shrinking margins and respiratory weakness weigh on profits.

QuidelOrtho Corporation (QDEL) Q4 2025 Earnings Call Transcript

QuidelOrtho (QDEL) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.63 per share a year ago.